


Leading the Future of Drug Development

Resverlogix is a global leader in developing epigenetic therapies to improve the health and well-being of people suffering from chronic illnesses.

By harnessing the ability of epigenetic therapies to correct flawed signals within our cells, we can effectively regulate the expression of disease-causing genes.



Apabetalone:

A thoroughly characterized, de-risked asset with a track record of safety and efficacy



Robust Intellectual Property Protection (to 2041)



FDA Breakthrough Therapy Designation



40+ peer-reviewed publications (incl. **Cell**, **Nature**)



4200+ patient-years of FDA-reviewed safety data



Detailed proteomic & transcriptomic analyses

Apabetalone: Designed to Regulate Gene Expression

An oral therapy with the ability to normalize the dysregulated epigenetics, our lead clinical candidate, apabetalone, has the potential to address critical unmet need across numerous chronic diseases.

Apabetalone has multiple patent protections until 2041, and an established record of clinical safety accumulated over 10 studies totaling more than 4200 patient-years.

Breakthrough Therapy Designation

Apabetalone is the first therapy of its kind to receive breakthrough therapy designation from the US Food and Drug Administration for high-risk cardiovascular disease



Without Altering DNA

Apabetalone targets the epigenetic dysregulation at the root of chronic disease



Epigenetic Mechanism

Through inhibition BET proteins, apabetalone acts at the level of gene transcription



Acting Upstream

Conventional pharmaceuticals target single proteins, while apabetalone can benefit multiple dysregulated pathways

| Indication | Phase 1 | Phase 2 | Phase 3 |
|--|----------------------------------|--|--|
| High-Risk Cardiovascular Disease <i>Type 2 Diabetes and Recent Acute Coronary Syndrome</i> | | ASSERT [2b] SUSTAIN [2b] ASSURE [2b] | BETonMACE <i>(Completed)</i> BETonMACE2 <i>(Ready)</i> |
| Chronic Kidney Disease <i>Type 2 Diabetes, Cardiovascular Disease and Renal Impairment</i> | | | BETonCKD <i>(Ready)</i> |
| Post COVID-19 Conditions | | | Phase2/3 <i>(Planned)</i> |
| PAH | APPRoACH-p <i>(Completed)</i> | APPRoACH-2 <i>(Planned)</i> | |
| Vascular Dementia | | | BETonMACE <i>(Subgroup)</i> |
| Combined Patient-years of Safety Data | | | 4200 |

Recent Updates

September 3, 2024

Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024

January 11, 2024

Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits

October 4, 2023

Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

We Thrive on Our Solid Partnerships



Our Management Team



Donald J. McCaffrey
 President & Chief Executive Officer
 Co-Founder



Dr Ewelina Kulikowski
 PhD
 Chief Scientific Officer



Brad Cann
 CPA, CA, CBV
 Chief Financial Officer



Dr Michael Sweeney
 MD
 SVP, Clinical Development



Dr Henrik C. Hansen
 PhD
 VP, Intellectual Property



Dr Ravi Jahagirdar
 DVM, MS
 VP, Pharmacology, Toxicology & Safety

Contact Information

✉ ir@resverlogix.com

☎ 403 254 9252

Follow Us

🐦 [@Resverlogix_RVX](https://twitter.com/Resverlogix_RVX)

🌐 linkedin.com/company/resverlogix-corp/